Literature DB >> 1287116

Fc gamma receptors in cancer and infectious disease.

M W Fanger1, D V Erbe.   

Abstract

Through interaction with antibody, IgG Fc receptors provide an interface between specific humoral immunity and Fc gamma R-bearing host cells. Fc gamma R trigger such diverse functions as immune complex clearance, phagocytosis of opsonized pathogens, reactive oxygen intermediate and enzyme secretion, and antibody-dependent cellular cytotoxicity (ADCC). Moreover, Fc gamma R are the exclusive trigger molecules for tumor cell killing by human myeloid cells. Studies of Fc gamma R function have been aided by the use of bispecific antibodies to link cells or pathogens to specific host cell molecules, including Fc gamma R. These reagents have permitted determination of the role of Fc gamma R in ADCC of the protozoan, Toxoplasma gondii, by human effector cells. This approach has also indicated that Fc gamma R do not serve as entry points for viruses such as dengue virus and HIV. Taken together, these results provide insight into the utility of manipulating Fc gamma R function in the therapy of cancer and infectious disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287116     DOI: 10.1007/bf02919127

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  86 in total

1.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

2.  Molecular cloning of a human immunoglobulin G Fc receptor.

Authors:  M L Hibbs; L Bonadonna; B M Scott; I F McKenzie; P M Hogarth
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids.

Authors:  K C Petroni; L Shen; P M Guyre
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

4.  Direct stimulation of ADCC by cloned gamma interferon is not ablated by glucocorticoids: studies using a human monocyte-like cell line (U-937).

Authors:  L Shen; P M Guyre; M W Fanger
Journal:  Mol Immunol       Date:  1984-02       Impact factor: 4.407

5.  The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells.

Authors:  D V Erbe; J E Collins; L Shen; R F Graziano; M W Fanger
Journal:  Mol Immunol       Date:  1990-01       Impact factor: 4.407

6.  Human monocytes and U937 cells bear two distinct Fc receptors for IgG.

Authors:  R J Looney; G N Abraham; C L Anderson
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells.

Authors:  D Herlyn; J Powe; A H Ross; M Herlyn; H Koprowski
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

8.  Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG.

Authors:  L Shen; P M Guyre; C L Anderson; M W Fanger
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

9.  Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes.

Authors:  C L Anderson; L Shen; D M Eicher; M D Wewers; J K Gill
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells.

Authors:  B Perussia; E T Dayton; R Lazarus; V Fanning; G Trinchieri
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  2 in total

Review 1.  The biology and pathology of Fc receptors.

Authors:  M Sandor; R G Lynch
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

2.  Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Authors:  Steven E Justiniano; Saranya Elavazhagan; Kavin Fatehchand; Prexy Shah; Payal Mehta; Julie M Roda; Xiaokui Mo; Carolyn Cheney; Erin Hertlein; Timothy D Eubank; Clay Marsh; Natarajan Muthusamy; Jonathan P Butchar; John C Byrd; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2013-07-31       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.